Basic Study
Copyright ©The Author(s) 2020.
World J Gastrointest Pathophysiol. Mar 13, 2020; 11(1): 1-19
Published online Mar 13, 2020. doi: 10.4291/wjgp.v11.i1.1
Figure 5
Full Size Figure Download Figure
Figure 5 BPC 157 counteracts ascites (mL), serum enzyme levels (U/L), hepatomegaly and splenomegaly (mean ± SD), stomach, duodenal, jejunal, ileal, cecal and ascending colon lesions (scored 0–5; Min/Med/Max), following suprahepatic occlusion of the inferior vena cava. Assessment at 15 min, 24 h and 48 h post-ligation. Treatment with 10 µg/kg BPC 157 (gray bars), 10 ng/kg BPC 157 (black bars), or saline (1 mL/rat; white bars) as a bath administration given at 1 min ligation. aP < 0.05 vs control.
  • Citation: Gojkovic S, Krezic I, Vrdoljak B, Malekinusic D, Barisic I, Petrovic A, Horvat Pavlov K, Kolovrat M, Duzel A, Knezevic M, Kasnik Kovac K, Drmic D, Batelja Vuletic L, Kokot A, Boban Blagaic A, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats. World J Gastrointest Pathophysiol 2020; 11(1): 1-19
  • URL: https://www.wjgnet.com/2150-5330/full/v11/i1/1.htm
  • DOI: https://dx.doi.org/10.4291/wjgp.v11.i1.1